MindWalk Holdings (HYFT) Net Cash Flow (2023 - 2026)
MindWalk Holdings (HYFT) posted quarterly Net Cash Flow of $17.8 million for Q2 2026, up 1421.76% year-over-year from $1.2 million in Q2 2025, and up 184.72% quarter-over-quarter from -$21.0 million in Q1 2026.
MindWalk Holdings (HYFT) Net Cash Flow (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Net Cash Flow for 4 consecutive years, with $17.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Cash Flow rose 1421.76% year-over-year to $17.8 million; the TTM figure through Apr 2026 stood at $1.0 million (down 80.71% YoY), while the FY2026 annual figure was $873218.7, down 84.17% from the prior year.
- Net Cash Flow climbed to $17.8 million in Q2 2026 per HYFT's latest filing, from -$21.0 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $17.8 million in Q2 2026 and bottomed at -$21.0 million in Q1 2026.
- Historically, Net Cash Flow has averaged -$111143.1 across 4 years, with a median of -$668663.2 in 2023.
- On a YoY basis, Net Cash Flow climbed as much as 4666.47% in 2025 and fell as far as 945.92% in 2025.
- MindWalk Holdings' Net Cash Flow stood at -$471996.1 in 2023, then jumped by 62.76% to -$175749.3 in 2024, then jumped by 4666.47% to $8.0 million in 2025, then soared by 121.86% to $17.8 million in 2026.
- Business Quant data shows HYFT's Net Cash Flow at $17.8 million in Q2 2026, -$21.0 million in Q1 2026, and $8.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -170.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 17.81 Mn |
| Apr 30, 2026 | 17.81 Mn |
| Jan 31, 2026 | -21.02 Mn |
| Jan 31, 2026 | -21.02 Mn |
| Oct 31, 2025 | 8.03 Mn |
| Oct 31, 2025 | 8.03 Mn |
| Jul 31, 2025 | -3.77 Mn |
| Jul 31, 2025 | -3.77 Mn |
| Apr 30, 2025 | -1.35 Mn |
| Apr 30, 2025 | -1.35 Mn |
| Jan 31, 2025 | 6.50 Mn |
| Jan 31, 2025 | 6.50 Mn |
| Oct 31, 2024 | -175,749.29 |
| Oct 31, 2024 | -175,749.29 |
| Jul 31, 2024 | 445,490.30 |
| Jul 31, 2024 | 445,490.30 |
| Apr 30, 2024 | -1.16 Mn |
| Apr 30, 2024 | -1.16 Mn |
| Jan 31, 2024 | -267,779.18 |
| Jan 31, 2024 | -267,779.18 |